Skip to main content

Carlsmed

ApplicationCarlsbad, CA, USAFounded 2018· One of 690 Application companies tracked by AMPulse

AI-enabled personalized spine surgery platform that uses patient CT/MRI scans to design and 3D-print custom titanium fusion implants (aprevo®), reducing surgical complexity and improving outcomes.

CEO / Founder
Mike Cordonnier
Team Size
51-200
Stage
Public
Total Funding
$143M
Latest Round
IPO
Key Investors
Cove Fund II; B Capital Group

Technology & Products

Key Products

aprevo® Technology Platform; aprevo® Lumbar Fusion Devices; aprevo® Cervical Fusion Devices; aprevo® Bi-lateral Posterior Lumbar Devices

Technological Advantage

Proprietary AI planning software and patient-specific implant design, protected by multiple patents (e.g., US11112770B2). The integration of digital planning with additive manufacturing creates a defensible workflow that is difficult to replicate, as it requires both software expertise and AM manufacturing capabilities.

Differentiation

Value Proposition

Reduces surgical time and complications by providing patient-specific 3D-printed titanium implants and AI-driven surgical plans, improving fusion rates and reducing revision surgeries, while enabling faster recovery and lower overall cost of care.

How They Differentiate

Unlike competitors offering standard implant lines, Carlsmed provides a fully personalized solution with AI-driven surgical planning and patient-specific 3D-printed titanium implants, reducing reliance on standard sizes and improving anatomical fit. This contrasts with Alphatec and Globus Medical, which primarily offer pre-sized implants with limited personalization.

Market & Competition

Target Customers

Spine surgeons and healthcare providers

Industry Verticals

Medical Devices; Spine Surgery

Competitors

Alphatec Spine; Globus Medical (NuVasive); Medtronic Spine

Growth & Milestones

Growth Metrics

Revenue grew 86% YoY to $50.5M in FY2025; Q1 2026 revenue $16.1M (+58% YoY); Q2 2026 revenue $18.9M.

Major Milestones

2020: Raised $2.5M seed round; 2021: Raised $10M Series A; 2022: Raised $30M Series B led by B Capital Group; 2025: IPO raised $100.5M on Nasdaq (CARL); 2026: Launched aprevo cervical fusion platform; merged with Precisive Surgical

Notable Customers

Scripps Memorial Hospital La Jolla; Hoag Orthopedic Institute; UC San Diego Health